Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Glaukos Corporation Common Stock
(NY:
GKOS
)
181.47
+1.44 (+0.80%)
Streaming Delayed Price
Updated: 12:28 PM EDT, Aug 10, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Glaukos Corporation Common Stock
< Previous
1
2
3
4
5
Next >
Glaukos Announces Second Quarter 2026 Financial Results
July 29, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt
July 27, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29
July 08, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis
June 25, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in Upcoming Investor Conferences
May 12, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces First Quarter 2026 Financial Results
April 29, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces the Release of its 2025 Sustainability Report
April 16, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos Receives Permanent J-code for Epioxa™
April 15, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29
April 08, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
April 06, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care
March 19, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results
February 17, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR
January 28, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17
January 20, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance
January 13, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in J.P. Morgan Healthcare Conference
December 16, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in Upcoming Investor Conferences
November 03, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Third Quarter 2025 Financial Results
October 29, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces FDA Approval of Epioxa™
October 20, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting
October 14, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29
October 08, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos Breaks Ground on New Research, Development, and Manufacturing Facility in Huntsville, Alabama
September 25, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in Wells Fargo Healthcare Conference
August 13, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Second Quarter 2025 Financial Results
July 30, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30
July 09, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies
June 25, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell
June 25, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in Upcoming Investor Conferences
May 13, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces First Quarter 2025 Financial Results
April 30, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
April 23, 2025
From
Glaukos Corporation
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
